Fragile X: leading the way for targeted treatments in autism. - Wikidata - awgldk - TriplyDB

Fragile X: leading the way for targeted treatments in autism.

Fragile X: leading the way for targeted treatments in autism.

http://www.wikidata.org/entity/Q30435321

about

Fragile x syndrome Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.Fragile X syndrome and targeted treatment trials.Unstable mutations in the FMR1 gene and the phenotypes RNA protein interaction in neurons The pathophysiology of fragile X (and what it teaches us about synapses)Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders GABAergic signaling as therapeutic target for autism spectrum disorders Inhibition-Based Biomarkers for Autism Spectrum Disorder.Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Translational animal models of autism and neurodevelopmental disorders.Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients.Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome Fragile X syndrome due to a missense mutation.Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Autworks: a cross-disease network biology application for Autism and related disorders.Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders Stress and the epigenetic landscape: a link to the pathobiology of human diseases?Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.FMR1 premutation and full mutation molecular mechanisms related to autism.Targeted treatments for fragile X syndrome.Translating glutamate: from pathophysiology to treatment.Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities.GABA system dysfunction in autism and related disorders: from synapse to symptoms Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone.Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS).Signaling defects in iPSC-derived fragile X premutation neurons Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review Maternal predictors of anxiety risk in young males with fragile X TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue Defining genetically meaningful language and personality traits in relatives of individuals with fragile X syndrome and relatives of individuals with autism.

P2860

Q24633000-7B631E3E-C226-4C4D-978C-6E854623C025 Q26853083-135527DD-DD3E-4F2F-8823-5C3BB2B149B4 Q26865162-E60F1BE1-523D-4035-AB55-E4D99563C8B0 Q26996649-91A3B168-AFE7-411D-AD23-9182A77060E5 Q27001674-9C6123FE-2215-4981-913E-7CD892BB027C Q27010675-442B3B27-0C63-413D-AB8C-328A78896F15 Q27011565-EC17DFC9-7112-496D-8D44-0F14D71DB37C Q27013583-77657835-2946-4BE8-AA60-972A2D514D8A Q27015696-DF0879F2-D677-4837-B26D-6729304DA03A Q27023257-6901D2D0-7501-4CE7-8811-36C722B9D375 Q27337360-8300177A-193A-4E3F-94F7-A19046ABC7C6 Q28086869-002BEDB2-7B1E-4331-80E9-97F057B02D07 Q30363617-F9A55E7D-ACA7-4637-9213-3DD7E2EA09AF Q30459992-6976953D-D47F-4EED-B8D4-0E53AF9E7306 Q33572001-6EAB140E-BFFE-4890-8EAC-C74BDFBA9DDF Q34198650-82DA7AE4-5EB3-46A1-A463-03E615EEF3B2 Q34200757-DE7D5D6F-324A-41AF-AD6A-EFB76AE1349F Q34215629-D2ED7021-94C2-480B-A02D-F4D8AACB75A3 Q34230612-9CA5EA9C-19AD-43EA-AC6D-83C22A56037A Q34494739-AF163081-FDD1-447C-8644-26EA3E0847F5 Q34871401-5FA18552-2010-4C2E-80AA-39C99B3749F8 Q34924426-9F8B42B4-AA84-455C-BF5B-25D6027E328B Q35009426-066A2CC4-20C2-4DF2-8888-ACCF1B6668BA Q35140542-3704982D-4539-42D2-A1D5-3CFE17ECD4F3 Q35232638-DF520D4C-8F93-4810-B57E-62A398374588 Q35614072-633577AC-8187-46E3-9D8F-7C794C366F45 Q35638949-8A17E57E-0CE3-4642-9EA1-803D711B4F2B Q35680720-13491584-6E03-4F52-BA35-542F79BB89B0 Q35680726-EDC56014-170C-47E2-8BB3-881656D6547A Q35739457-0CA29F08-D3FC-42E0-A548-7B59E3B34D8B Q35765423-EFF92721-4AEC-42BE-BE2D-D073B257B952 Q35770888-9430974E-DEDA-43D8-8C37-D51E90D222CE Q36026897-FDC23992-496A-419E-927E-D78B8CCEE0D7 Q36028872-A4B692F7-8841-42F4-8860-EDA8ABD2C4E9 Q36142068-BA7674A4-61E7-4EE7-ADD0-D11E4E2B89A8 Q36169046-811B917F-56C9-4F52-8A6C-414CAC423190 Q36377095-10CA3746-B46B-42B6-9ED1-4B3A82562071 Q36399716-ABF43480-E3BA-4773-A7A9-F89EF18AEFFD Q36925690-A8F17AE7-9851-4139-B3DB-474B4134B0AD Q37088013-9EFE3078-5117-44EE-B644-4A616F337F71

P2860

Fragile X: leading the way for targeted treatments in autism.

http://www.wikidata.org/entity/Q30435321

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Fragile X: leading the way for targeted treatments in autism.

@ast

Fragile X: leading the way for targeted treatments in autism.

@en

type

label

Fragile X: leading the way for targeted treatments in autism.

@ast

Fragile X: leading the way for targeted treatments in autism.

@en

prefLabel

Fragile X: leading the way for targeted treatments in autism.

@ast

Fragile X: leading the way for targeted treatments in autism.

@en

P1433

Q30435321-208146F4-7D47-4407-9239-3F441DE92643

P1476

Q30435321-BCC504AE-50B2-4FF4-A0E3-5A27E857F0BC

P2093

Q30435321-1784C9E4-6CEB-4457-BE5E-FA4B9D97342C

Q30435321-73647775-3784-4F7F-8AD4-F7BC08FB595F

Q30435321-BFA081A8-A472-44F8-90A1-425C4E25BDC3

P2860

Q30435321-0075DD90-66BC-4B71-88EF-8F0309EBA9F3

Q30435321-011AA88C-4023-41F8-A6F8-668E687CB5CB

Q30435321-0299A4E5-99A1-4428-B535-DE9EFD439F3A

Q30435321-04E99130-A362-4575-A99F-377F6D909EA6

Q30435321-09226406-F0CF-489D-A003-AF5A6D5C33F7

Q30435321-09D83208-89C0-4937-BF0E-9C91E74AE161

Q30435321-0A5B2A36-D4CC-462E-91C1-FE004DB81CD8

Q30435321-0DD3F361-0D38-4BDB-91D5-B174CECB73C8

Q30435321-0ED5B6D0-7595-4376-91DE-8A8896706767

Q30435321-0F46D59B-176B-4F15-8B9A-85F977F72C75

P2888

Q30435321-3401E796-0863-4A7A-9DAD-5EAF055D1C86

P304

Q30435321-582A6CA5-1D01-4E3D-94B2-55BD40B7E8BC

P31

Q30435321-7DAA4152-A865-41F1-A9A7-58F295D21145

P356

Q30435321-EF0E0D62-C3E5-4A99-886F-2C6E14C390DE

P433

Q30435321-9D6B0D6E-7B66-4852-B770-D8593E2F24AC

P478

Q30435321-F38A1DF5-B56F-402E-B2CF-8256F1526988

P577

Q30435321-06311EEE-071B-4F76-B0A3-3853E48E306F

P5875

Q30435321-C4EAA007-A41E-40B5-9CC4-F0DC3E02D4CA

P6179

Q30435321-7795CE4B-402E-48EC-9ABB-42F33BF8B52D

P698

Q30435321-E4A02005-3D25-48AB-8D4D-6106CABA9E5E

P921

Q30435321-8AB659AA-E6E3-4E96-BAA1-CB86AE157069

P932

Q30435321-18EFD80E-F4A1-4827-BEA3-32DC2151BFAC

P356

J.NURT.2010.05.005

P1433

Neurotherapeutics

P1476

Fragile X: leading the way for targeted treatments in autism.

@en

P2093

Elizabeth Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

Lulu W Wang

http://www.w3.org/2001/XMLSchema#string

Randi J Hagerman

http://www.w3.org/2001/XMLSchema#string

P2860

Fragile X: translation in action

Correction of fragile X syndrome in mice.

Altered synaptic plasticity in a mouse model of fragile X mental retardation

Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation

Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function

Advances in the treatment of fragile X syndrome

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits

Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X

Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations

P2888

j.nurt.2010.05.005

P304

264-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2010.05.005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45274548

http://www.w3.org/2001/XMLSchema#string

P6179

1023948215

http://www.w3.org/2001/XMLSchema#string

P698

20643379

http://www.w3.org/2001/XMLSchema#string

P921

P932

4084556

http://www.w3.org/2001/XMLSchema#string